The extended Prescription Drug User Fee Act action date is now May 12, 2027, Belite Bio said. The clinical-stage drug developer said the FDA needs more time to review information submitted in support of the new drug application.
If the agency identifies no major deficiencies during its ongoing review, it plans to communicate proposed labeling requests and any anticipated postmarketing requirement requests, if necessary, to the company by April 12, 2027.
Belite Bio said it is confident in the clinical evidence supporting tinlarebant and in the drug’s potential to address significant unmet medical need among people with STGD1.




Comments (0)
No comments yet. Be the first!